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Abstract
Background: Peri-operative inflammation has been extensively highlighted in cancer patients as detrimental. Treatment
strategies to improve survival for cancer patients through targeting peri-operative inflammation have yet to be devised.
Methods: We conducted a multi-centre, randomised controlled clinical trial using Taurolidine in non-metastatic colon
cancer patients. Patients were randomly assigned to receive Taurolidine or a placebo. The primary endpoint for the study
was the mean difference in day 1 IL-6 levels. Secondary clinical endpoints included rates of post-operative infections and
tumor recurrence.
Results: A total of 293 patients were screened for trial inclusion. Sixty patients were randomised. Twenty-eight patients
were randomised to placebo and 32 patients to Taurolidine. IL-6 levels were equivalent on day 1 post-operatively in both
groups. However, IL-6 levels were significantly attenuated over the 7 day study period in the Taurolidine group compared
to placebo (p = 0.04). In addition, IL-6 levels were significantly lower at day 7 in the Taurolidine group (p = 0.04). There
were 2 recurrences in the placebo group at 2 years and 1 in the Taurolidine group. The median time to recurrence was
19 months in the Placebo group and 38 months in the Taurolidine group (p = 0.27). Surgical site infection was reduced in
the Taurolidine treated group (p = 0.09).
Conclusion: Peri-operative use of Taurolidine significantly attenuated circulating IL-6 levels in the initial 7 day post-
operative period in a safe manner. Future studies are required to establish the impact of IL-6 attenuation on survival
outcomes in colon cancer.
Trial registration: The trial was registered with EudraCT (year = 2008, registration number = 005570–12) and ISRCTN
(year = 2008, registration number = 77,829,558).
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Background
Peri-operative inflammation is a phenomenon that has
been extensively highlighted in cancer patients as a po-
tential therapeutic target [1–3]. Strong links have been
demonstrated between the pro-inflammatory compo-
nents of the peri-operative inflammatory milieu and
their effects locally on residual tumor cell deposits and
systemically on disseminated tumor cells [4–9].
However, treatment strategies aimed at potentially im-
proving survival for cancer patients by targeting
peri-operative inflammation have yet to be devised, with
the majority of treatment strategies aimed only at the
neoadjuvant and adjuvant period.
The peri-operative inflammatory response itself is vital
for the healing process, however several components of
the inflammatory cascade initiated by surgical trauma
confer accelerant effects on residual tumor deposits [10–
15]. In particular, the pro-inflammatory cytokine IL-6 has
been demonstrated to act as a key mediator in tumor cell
growth by upregulation of metastatic gene expression and
further stimulation of down-stream pro-inflammatory cy-
tokines and growth factor release [16]. Tumor derived
IL-6 also acts as a chemoattractant to circulating tumor
cells and facilitates self-seeding of disseminated tumor
cells [17, 18]. Moreover, elevated levels of IL-6 carry prog-
nostic implications in certain tumor phenotypes including
colon cancer, with elevated IL-6 levels closely associated
with increasing tumor size, tumor stage, presence of meta-
static disease and reduced survival [19].
Up to 30% of non-metastatic colon cancer patients can
develop distant metastases. In particular, 70% of metastases
will occur within 2 years of the initial ‘curative’ operation.
This pattern is thought to relate to the effects of surgical in-
flammation [20, 21]. The best illustration of this cause-effect
relationship is demonstrable where complications such as
anastomotic leakage occur or where conversion from lap-
aroscopic to open surgery is necessary [22]. In these scenar-
ios patients experience a more exaggerated inflammatory
response and ultimately have a worse outcome [23, 24].
Thus, colon cancer offers an ideal model to investigate the
potential therapeutic effects of targeting inflammation.
To explore the concept of attenuating inflammation
safely in cancer patients undergoing major surgery we
chose the ubiquitously active agent Taurolidine which
has been extensively studied in a variety of clinical states
involved in inflammation and cancer with a remarkable
safety record [25]. Taurolidine itself possesses both
anti-inflammatory and anti-neoplastic properties and has
an excellent safety profile [26–28]. Our pre-clinical ex-
perience of the anti-inflammatory effects of Taurolidine
were in an experimental pancreatitis model where Taur-
olidine reduced the endotoxin levels in an animal model
[29]. Other groups have shown a reduction in
pro-inflammatory mediators including IL-1 and TNF-α
associated with Taurolidine administration [30]. In
addition, our group has demonstrated previously in the
setting of a randomised clinical trial that peri-operative
IL-6 can be safely and successfully targeted using this
anti-inflammatory agent in patients undergoing coronary
artery bypass surgery [31].
On this basis we hypothesised that peri-adjunctive
utilisation of a dual anti-inflammatory and anti-neoplas-
tic agent, Taurolidine, could potentially reduce immedi-
ate peri-operative inflammation which may confer
survival benefits for colon cancer patients. Thus, to test
this hypothesis, we performed a randomised, controlled
clinical trial to examine the efficacy of using an
anti-neoplastic agent on peri-operative inflammation in
non-metastatic colon cancer patients undergoing resec-
tion of their primary tumor. We conceptualised the term
‘surguvant’ to define therapeutic modification used in
combination with surgical treatment during the
peri-operative period. We also sought to examine patient
safety peri-operatively and observe the effects of this
treatment strategy on disease free survival.
Methods
Trial design
A randomised, multicentre, placebo controlled, open
label clinical trial was performed. Three centres re-
cruited patients including Cork University Hospital,
Bons Secours Cork and Mercy University Hospital. Pa-
tients were randomised on a 1:1 allocation ratio to 2%
Taurolidine infusions or to a placebo, given 4 times a
day for a total of 4 days. A sealed envelope method was
used for randomisation. Randomisation codes were gen-
erated from www.randomization.com.
The investigational medicinal product was an intra-
venous formulation of 2% Taurolidine (C7H16N4O4S2)
manufactured by Geistlich-Pharma AG, CH 6110
Wolhusen/Luzern, Switzerland. The comparator pla-
cebo was 0.9% saline. The Taurolidine solution required
central administration and all patients randomised to
receive Taurolidine had either a central line or a periph-
eral long line inserted prior to the operation. First dose
of Taurolidine or Placebo was administered at induc-
tion of anaesthesia. Trial bloods were performed
pre-operatively, and at 3 h, 6 h, day 1, day 2, day3, day
5 and day 7 (only if still an inpatient) post-operatively.
Human IFN-γ, IL-1β, IL-2, IL-6, IL-10, TNF-α, Human
VEGF, Human CRP levels were measured using a cus-
tomised ELISA kit manufactured by MSD (Meso Scale
Discovery)® (Gaithersburg, Maryland, US).
Inclusion/exclusion criteria
Inclusion criteria included males and females between
18 and 85 years of age with non-metastatic colon cancer.
Patients undergoing elective surgery only were included.
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Exclusion criteria were as follows - Rectal cancers
(defined as a tumor < 15 cm from the anal verge), pa-
tients with a known allergy to taurolidine / taurine,
pregnant and lactating women, evidence of underlying
liver disease (abnormal LFT’s (> × 2 normal), INR > 1.5),
evidence of underlying renal disease (creatinine > 180 for
women, > 150 for men), blood dyscrasia (neutropenia < 1500
cells /cm3, thrombocytopenia < 100,000 cells/cm3),
evidence of intestinal obstruction, metastases (M1:Distant
spread or Dukes D), morbid obesity (body mass index
> 40 kg/m2), operative risk > ASA – III, previous can-
cer / malignant disease other than non-melanoma
skin cancer, coexisting active inflammatory disorder
(including active RA, IBD, SLE), corticosteroids usage,
immunosuppressive drugs, previous diagnosis of HIV,
chronic active Hepatitis B or C (testing not required
for study), active infection at the time of surgical
intervention.
Endpoints
The primary endpoint for the study was the difference in
mean plasma IL-6 levels on day 1 in Taurolidine as com-
pared to placebo group, adjusted for pre-operative IL-6,
age and gender. Secondary laboratory endpoints included
the difference in mean IL-6, IL-10 and CRP measured on
post- operative days 2, 3, 5 and 7 in the Taurolidine as
compared to the placebo group, adjusted for baseline
measurement, age, gender and procedure type.
Exploratory analyses were conducted examining levels of
TNF-α, VEGF, IL-1β, IFN-γ, surface expression of CD14
and CD11b on neutrophils/monocytes, and plasma levels
of C-reactive protein at the above time points.
Secondary Clinical Endpoints included a comparison
of Taurolidine to control group with regard to occur-
rence & severity of post-operative infections, time to
bowel functional recovery, post-operative pain control
and recurrence (defined as local or metastatic growth) of
tumor growth.
Trial oversight
All patients provided full written informed consent.
Trial participation was approved in all 3 study sites
by the Cork Research Ethics Committee and the Irish
Medicines Board and was registered with EudraCT
(registration number = 2008–005570-12) and ISRCTN
(registration number = 77,829,558). The trial was con-
ducted in accordance with the provisions of the
Declaration of Helsinki. A trial monitor was utilised
to ensure the accuracy of the data collected and the
case report form from each patient.
Sample size
Precise sample size and power estimation for the trial
was limited by lack of data within available literature de-
scribing expected baseline and follow-up levels of the
various biochemical outcome parameters in the
Fig. 1 Consort diagram
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proposed study population and lack of available evidence
regarding the efficacy of the intervention within this set-
ting. Based on the changes in IL-6 levels following co-
lonic resection observed by Salvadora Delgado, M.D. et
al. [32], we estimated that 28 patients in each arm would
allow us to detect a 0.75 SD difference in study arms
with 80% power, given a type 1 error rate of 5%, using a
two sample t-test with equal samples sizes and a shared
variance.
Statistical analysis
Categorical data were described by their counts and per-
centages in each category. Continuous variables were de-
scribed by their medians and inter-quartile ranges. All
continuously measured laboratory endpoints were log
transformed. Differences between study arms for labora-
tory endpoints, at each time point specified in the proto-
col, were estimated using ANCOVA, with adjustment
for baseline measurement, age, sex, and procedure. Dif-
ferences between study arms in linear trajectories of la-
boratory endpoints across all time-points (days 1–7)
were estimated using linear mixed effects models using a
treatment arm by Time interaction term. These models
were adjusted for age, sex, and procedure type. The stat-
istical significance of the interaction was tested using the
p-value from the likelihood ratio chi-squared test.
Differences between study arms for categorical clinical
endpoints were assessed using the chi-squared test. Dif-
ferences between study arms for time-to-recurrence and
mortality were estimated using the Cox proportional
hazards model, adjusted for age, sex, and procedure.
All analyses were conducted on an intent-to-treat
basis, using the R Project for Statistical Computing
(version 3.2.2 R Foundation for Statistical Computing,
Vienna, Austria. www.r-project.org/).
Results
A total of 293 patients were screened for trial inclusion.
Two hundred thirty three patients were excluded, thus
60 patients were randomised to either study group
(Fig. 1). Twenty-eight patients were randomised to pla-
cebo and 32 patients to Taurolidine. The patient, tumor
and operative characteristics are summarised in Table 1.
There was no significant difference in these characteris-
tics between the two study arms.
Primary endpoint and post-hoc analysis
A peak in IL-6 levels in both study groups was evident
at 24 h post surgery. The overall trend for this IL-6 peak
was to settle over the remaining study days. IL-6 levels
at 24 h were equivalent in the Taurolidine and placebo
group (p = 0.89). Post-hoc analysis was performed to
analyse the selected study cytokines in both study groups
over the entire 7 day study period (Fig. 2). IL-6 levels
were found to be significantly attenuated in the Tauroli-
dine group compared to the placebo group over the
course of the study period (p = 0.04). In addition, the
mean levels of IL-6 were significantly attenuated in the
Taurolidine group compared to placebo at 7 days (p = 0.04).
Secondary laboratory end-points
TNF-α levels demonstrated a peak at 24 h post surgery.
The rate of TNF-α attenuation in Taurolidine treated pa-
tients compared to placebo over the 7 days approached
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27 (45%) 12 (42.8%) 15 (55.6%) 0.55
Right
hemicolectomy
23 (38.3%) 12 (42.8%) 11 (40.7%)
Total
colectomy
1 (1.7%) 0(0%) 1 (3.7%)
Other 9 (15%) 4 (14.2%) 5 (15.6%)
Procedure
Converted 6 (10%) 3 (10.7%) 3 (9.4%) 0.59
Lap 47 (78.3%) 23 (82.1%) 24 (75%)
Open 7 (11.7%) 2 (7.1%) 5 (15.6%)
Primary tumor
T1 4 (6.7%) 1 (3.6%) 3 (9.3%) 0.59
T2 8 (13.3%) 5 (17.8%) 3 (9.3%)
T3 34 (56.6%) 16 (57.1%) 18 (56.2%)
T4 8 (13.3%) 2 (7.1%) 6 (18.8%)
T4a 4 (6.7%) 3 (10.7%) 1 (3.2%)
T4b 1 (1.7%) 1 (3.5%) 0 (0%)
Carcinoid 1 (1.7%) 0 (0%) 1 (3.2%)
Regional lymph nodes
N0 31 (51.6%) 12 (42.8%) 19 (59.4%) 0.37
N1 9 (15%) 5 (17.8%) 4 (12.5%)
N1a 7 (11.6%) 4 (14.2%) 3 (9.4%)
N1b 6 (10.0%) 3 (10.8%) 3 (9.4%)
N2 5 (8.4%) 3 (10.8%) 2 (6.2%)
N2b 2 (3.4%) 1 (3.6%) 1 (3.1%)
Lymph node yield 17 16 18 0.58
Follow-up
(months)
34 32 37 0.23
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significance (p = 0.07). At the 7 day time point, IL-2
demonstrated a trend towards attenuation in the
Taurolidine treated group compared to placebo (p = 0.06).
The remaining cytokines and growth factors did not show
any significant changes over the study period between the
two study groups.
Secondary clinical end-points
The median length of stay was 6 days for the entire
study cohort. There were 11 cases of post-operative in-
fective complications. Six of the infective complications
were surgical site infections, 5 cases were in the placebo
group and 1 in the Taurolidine group (p = 0.09) (Table 2).
Three post-operative infections were anastomotic leaks,
2 in the placebo and 1 in the Taurolidine treated group
(p = 0.41). The remaining 2 infective complications con-
sisted of a lower respiratory tract infection in a patient
with underlying COPD and cellulitis at the site of PICC
line insertion. Both of these infective complications were
in the Taurolidine group.
The mean time to return of bowel function was 39 h
in the placebo group and 34 h in the Taurolidine group
(p = 0.32). Pain scores demonstrated no difference be-
tween the two study groups (p = 0.39).
Survival end-points
At the 2 year follow-up time point there were 3 recurrences
in total, 2 in the placebo group and 1 in the Taurolidine
group (p = 0.38) (Table 3). The overall median follow-up at
the time of data analysis was 34 months (range 24 months
to 5 years). The median follow-up time in the placebo
group was 32 months (range 24–76 months). The median
follow-up time in the Taurolidine group was 37 months
(range 24–76 months). In this time period 6 patients had
experienced a recurrence, with 3 in the placebo treated
group and 3 in the Taurolidine group (p = 0.64). In these
patients the median time to recurrence was 19 months in
the placebo group and 38 months in the Taurolidine group
(p = 0.27). The 3 placebo group patients developed
Fig. 2 Seven-day linear trends in laboratory endpoints. Differences in the 7-day linear trend between treatment arms were tested using linear
mixed effects models and treatment X time interaction term. The p-values in the plot are from the likelihood ratio test for a model including that
interaction term vs. a model without it








Overall recurrence 6 3 3 1
Recurrence at 2 years 3 2 1 0.389
Mean time to recurrence
(months)
16.3 28.6 0.4
Median time to recurrence
(months)
19 38 0.268






Pain Day 1 2.5 1.8 0.391
Day 2 1.9 2 0.873
Day 3 1.9 1 0.179
Time to bowel function (hrs) 39 34 0.32
Infective complication 8 4 0.19
Surgical site infection 5 1 0.09
Anastomotic leak 2 1 0.59
Other 0 2 0.49
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loco-regional recurrence. The 3 Taurolidine patients devel-
oped distant metastatic disease.
Discussion
This multi-centre, randomised clinical trial was specific-
ally designed to address the question of the potential ef-
fects of surgically induced inflammation on
perioperative tumor kinetics using IL-6 as a surrogate
marker. We used the agent Taurolidine to therapeutic-
ally modify these effects during the peri-operative time
period. Although there was no difference seen at the
early 24 h time-point, post hoc analysis demonstrated a
significant trend for IL-6 attenuation over the 7 day
post-operative period in Taurolidine versus the control
group, with levels being significantly different at
post-operative day 7. Thus whilst we do not demonstrate
an immediate post-operative effect, in post hoc analysis
we see a delayed effect from Taurolidine on circulating
Il-6 levels.
The levels of circulating colon cancer cells and circulating
colon cancer stem cells are significantly higher
peri-operatively, particularly within the portal venous sys-
tem [33, 34]. Together with a surge in circulating
pro-inflammatory cytokine and growth factor levels, this is
a significant and completely understudied phenomenon
that potentially has detrimental implications for cancer pa-
tients in both the short and long term. This trial provides
evidence, at least in part, that targeting the inflammatory
response in particular can potentially reduce post-operative
tumor metastatic growth resulting in improved patient sur-
vival outcome. In particular it can reduce inflammation and
ultimately may improve patient outcome.
Circulating levels of IL-6 were attenuated in response
to Taurolidine administration in a time dependent man-
ner. It is possible that earlier administration of Tauroli-
dine a number of days pre-operatively might result in a
more immediate attenuation of IL-6 post-operatively.
Furthermore, post-operative administration over an ex-
tended period of time may also have an added benefit in
the presence or absence of chemotherapy [35].
IL-6 can propagate colon cancer cell growth and un-
surprisingly circulating levels of IL-6 are prognostic in
colon cancer [36]. The present study was not powered
for a formal survival analysis so it is not possible to as-
sess the clinical impact of IL-6 attenuation, however in-
teresting trends are emerging from this data in relation
to survival outcome. The median time to tumor recur-
rence was longer, though not significantly different in
patients who were treated with Taurolidine versus those
that were treated with placebo (38 months versus
19 months). However, these are only trends and would
require an appropriately powered trial in order to draw
solid conclusions.
Surgical patients are dependent upon components of in-
flammation to heal safely. Compromise of the healing
process can lead to life-threatening complications, for ex-
ample an anastomotic leak. Unsuccessful attempts at uti-
lising the peri-operative period for adjunctive therapies
have failed in the past due to compromise of safety. The
present trial demonstrates that the anti-inflammatory
agent Taurolidine can target key pro-inflammatory cyto-
kines without compromising patient safety.
Several key points now need to be addressed. Firstly,
does extension of the period of Taurolidine administration
help to further attenuate pro-inflammatory responses to
surgical trauma. Careful attention to patient safety and
safety outcomes will be required if further extension of
the administration period is considered. Secondly, does
the attenuation of the inflammatory response translate
into a survival benefit? We hypothesise that the attenu-
ation of Il-6 levels over the initial post-operative week
may lead to a clinically relevant improvement in patient
outcomes as the peri-operative interaction of disseminated
tumor cells and the pro-inflammatory milieu of cytokines/
growth factors will occur in a less favourable environment.
However this needs to be further addressed in a large, ad-
equately powered clinical trial.
Conclusions
Peri-operative use of Taurolidine attenuated circulating
IL-6 levels in a progressive manner post-operatively. We
believe that further investigation of such ‘surguvant’
therapies during this under-investigated period could
lead to significant improvements in surgical patient out-
comes in a safe manner.
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